Stockscreener 앱 받기
0.00
100.00%
-6.75
시간 외 거래:
6.95
6.95
+
전일 마감가:
$6.75
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$26.62M
수익:
-
순이익/손실:
$-117.67M
주가수익비율:
0.00
EPS:
-3.09
순현금흐름:
$-101.06M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$8.36
Athira Pharma Inc Stock (ATHA) Company Profile
명칭
Athira Pharma Inc
전화
(425) 620-8501
주소
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare ATHA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATHA
Athira Pharma Inc
|
0.00 | 26.62M | 0 | -117.67M | -101.06M | -3.09 |
VRTX
Vertex Pharmaceuticals Inc
|
433.54 | 109.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
642.59 | 68.12B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
816.22 | 50.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.51 | 39.85B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.73 | 31.96B | 742.00K | -1.37B | -1.07B | -7.0731 |
Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2026-02-19 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-09-19 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-04 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-09-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 개시 | Rodman & Renshaw | Buy |
| 2022-10-17 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-06-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-06-23 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 개시 | BTIG Research | Buy |
| 2022-04-21 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Goldman | Neutral |
| 2020-10-13 | 개시 | Goldman | Buy |
| 2020-10-13 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-13 | 개시 | Jefferies | Buy |
| 2020-10-13 | 개시 | Stifel | Buy |
모두보기
Athira Pharma Inc 주식(ATHA)의 최신 뉴스
ADAR1, Daniel Schneeberger disclose 727,481 shares in LeonaBio (ATHA) - Stock Titan
TradingKey - TradingKey
LeonaBio (LONA) director receives 56,000 stock options at $9.63 strike - Stock Titan
Director at LeonaBio (LONA) granted 56,000 stock options - Stock Titan
Option grant gives LeonaBio (LONA) director 56,000 shares at $9.63 - Stock Titan
Natalie Holles named LeonaBio (LONA) director in initial Form 3 - Stock Titan
LeonaBio (LONA) director Peter B. Silverman files initial Form 3 - Stock Titan
LeonaBio (LONA) director Callori Fred files baseline Form 3 ownership report - Stock Titan
Perceptive Advisors (ATHA) caps LeonaBio stake at 19.99% and gains board seat - Stock Titan
LeonaBio (NASDAQ: ATHA) widens Q1 loss while funding late-stage trials - Stock Titan
LeonaBio Enhances Board of Directors with Appointments of - GlobeNewswire
ATHIRA PHARMA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Athira Pharma, Inc.ATH - TMX Newsfile
ATHIRA PHARMA SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Athira Pharma, Inc.ATH - TMX Newsfile
Athira Pharma (LONA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $LONA - MarketBeat
Independent Nonclinical Research on Lasofoxifene Presented - GlobeNewswire
LeonaBio CEO Litton sells $27,687 in shares - Investing.com
Athira Pharma (NASDAQ:LONA) Shares Down 6.5%Should You Sell? - MarketBeat
28,000-share stock option grant to LeonaBio (LONA) director - Stock Titan
LeonaBio (LONA) awards 300,000 stock options to chief scientific officer - Stock Titan
28,000 stock options granted to LeonaBio (LONA) director Kosacz - Stock Titan
LeonaBio (LONA) director Grant Pickering receives 28,000 stock options - Stock Titan
Director Romano Kelly receives 28,000 LeonaBio (LONA) stock options at $9.54 - Stock Titan
LeonaBio (LONA) director receives options to buy 28,000 shares at $9.54 - Stock Titan
LeonaBio (LONA) director awarded options on 28,000 shares at $9.54 - Stock Titan
LeonaBio (LONA) grants CMO 350,000 options at $9.54 - Stock Titan
Director John M. Fluke Jr. receives 28,000-share option grant at LeonaBio (LONA) - Stock Titan
LeonaBio (LONA) awards 300,000 stock options to general counsel - Stock Titan
LeonaBio (LONA) CFO awarded 300,000 stock options at $9.54 - Stock Titan
LeonaBio (LONA) CEO awarded 750,000 stock options at $9.54 strike - Stock Titan
Sentiment Recap: Should I invest in Athira Pharma Inc before earningsQuarterly Portfolio Summary & Breakout Confirmation Alerts - baoquankhu1.vn
Market Outlook: What is the long term forecast for Athira Pharma Inc stockNew Guidance & Reliable Trade Execution Plans - baoquankhu1.vn
Top Athira Pharma (LONA) Competitors 2026 - MarketBeat
Athira Pharma, Inc. (LONA) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Mizuho raises LeonaBio stock price target to $16 on breast cancer drug outlook - Investing.com
Athira Pharma, Inc. (ATHA) Competitors - Meyka
[EFFECT] LeonaBio, Inc. SEC Filing - Stock Titan
Performance Recap: What is the PEG ratio of Athira Pharma Inc2026 Catalysts & Trade Opportunity Analysis Reports - baoquankhu1.vn
LeonaBio (NASDAQ: ATHA) registers 58.5M shares; warrants could yield $146M - Stock Titan
RSI Check: Is Athira Pharma Incs growth already priced in2026 Gainers & Reliable Price Action Trade Plans - baoquankhu1.vn
LeonaBio (ATHA) clears resale of 5.5M warrant shares for Sermonix - Stock Titan
LeonaBio (NASDAQ: LONA) files resale registration for PIPE warrant holders - Stock Titan
LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan
Income Plays: Can Athira Pharma Inc be recession proofEarnings Risk Report & Reliable Trade Execution Plans - baoquankhu1.vn
Aug Movers: Can Athira Pharma Inc expand into new markets2026 Market Trends & Weekly Market Pulse Alerts - baoquankhu1.vn
LeonaBio Reports 2025 Financial Results, Acquires Lasofoxifene License, and Advances Clinical Pipeline for Metastatic Breast Cancer and ALS 123 - Minichart
LeonaBio Updates Investors on 2025 Results and Strategy - TipRanks
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update - Bitget
LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - Stock Titan
LeonaBio lines up $90M and a 2027 readout for breast cancer drug - Stock Titan
Momentum Shift: Can Athira Pharma Inc be recession proof2026 Pullback Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) - Defense World
Athira Pharma Inc (ATHA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.72%
0.63%
자본화:
|
볼륨(24시간):